Category: Uncategorized

KUALA LUMPUR, March 26 (Bernama) — Hotel Maya Kuala Lumpur has whipped up traditional kampung delicacies this Hari Raya as a tribute to the signature delicacies from the different states and celebrating the multi-diversity of the different cultures in Malaysia.

“We are bringing the best of traditional Malay cuisines to Hotel Maya so that patrons may enjoy the best of Malaysia at the heart of Kuala Lumpur where our hotel is located. These unique dishes are available only during Hari Raya, and we aim to create a fulfilling and satisfying experience for all our valued patrons”, said General Manager, Sharmini Moganasundram.

Heading the specialised Raya menu is Chef Taib and Chef Hasbullah. Their signature Citarasa Simfoni Malaysia Buffet dinner will start from the 19^th of April until the 9^th of May from 6.30 to 10.30pm at Maya Brasserie. At RM90nett per person, patrons will have unlimited kampung favourites with 13 specialised stalls and more than 100 dishes. Signature dishes include Roast Lamb, Gear-Box Soup with delicious bone marrows; Fish Head Curry; Satay and Yong Tau Foo. Diners will be spoilt for choice when they visit the restaurant’s Warungs showcasing specialties from different locations in Kuala Lumpur. To start, diners will revel in traditional Malay Ulams, Kerabu, pickles and condiments. The Warung Aneka Sup which features heart-warming local soups such as Gear-box Soup and Bubur Lambuk. If you fancy grilled items, the Warung Bakar Bakar Lorong Binjai makes fresh grilled squid, chicken wings and a selection of fish with special condiments to complement each item. Malaysian tea time favourite is at Warung Lorong Cendana and Warung Goreng-Goreng Kampung Baru. Reminisce childhood snacks such as Pisang Goreng, Cekodok, Rojak and so much more. Continue the experience down memory lane with local sweets. Savour Ais Kacang, Cendol, Len Chi Kang, Ais Krim Potong, Sago Gula Melaka, Fruit Rojak and variety of local fruits. Senior citizens and children are entitled to 50% off and patrons are entitled to 20% off if they purchase by 12^th of April.

Besides the dine-in buffet spread, Hotel Maya is also offering takeaway and delivery for those who wish to stay in the comfort of their own homes. During the holy month, patrons can break their fast with the Simfoni Santapan Maya Set Menu which consist of three different sets namely Dedaun, Laman Bayu and Aman Sari. The sets are priced at RM60nett per person with 12 dishes (Dedaun), RM80nett per person with 13 dishes (Laman Bayu) and RM100nett per person with 14 dishes (Aman Sari). All sets come with appetisers, mains and dessert. There is a minimum order of 4 persons for each set ordered and patrons are entitled to 20% off if they purchase by the 12^th of April. The Simfoni Santapan Maya Set Menu is available from the 5^th of April to 12^th of May from 11am to 9pm (last order at 8pm).

Also, for delivery and takeaway the Simfoni Hari Raya Aidilfitri set menu consist of three different sets: Hijauan Desa, Jendela di Taman and Ditepi Pantai. The sets are priced at RM60nett per person with 12 dishes (Hijauan Desa), RM80nett per person with 13 dishes (Jendela di Taman) and RM100nett with 14 dishes (Ditepi Pantai). All sets come with appetisers, mains and dessert. There is a minimum order of 4 persons for each set ordered and patrons are entitled to 20% off if they purchase by the 12^th of May. The Simfoni Hari Raya Aidilfitri set menu is available from the 13^th May to 11^th of June from 11am to 9pm (last order at 8pm).

All set menus are required to order a day in advance and free delivery is provided up to 10km. Besides that, each set menu comes with a choice of 4 specially crafted infused bottled beverage. Patrons can choose from either Maya Asam Boi Cooler, Mahsuri Berry, Rimba Kiwi, Awan Biru and Sinaran Mentari. They are the perfect thirst quenchers and are deliciously refreshing with real fruits used as garnish.

A-la carte menu is available for delivery and take away during the festive celebration from 5^th of April until the 11^th of June. Must-haves include the Lemang with Chicken Rendang; Satay; Kambing Bakar; Rendang Tok; Kari Kepala Ikan Salmon; Penggat Pisang Bersama Sago among others. The ala carte menu is priced from RM10 onwards.

Kindly click here to download pictures:

SOURCE: SELANGOR DREDGING BERHAD

FOR MORE INFORMATION, PLEASE CONTACT:
Name: Anusha K.
Manager, Communications & Corporate Affairs
Tel: 012 201 5024
Email: anusha.k@sdb.com.my

–BERNAMA

KUALA LUMPUR, March 24 (Bernama) — I remember when I was in primary school, the teacher asked us to imagine and draw something about Wawasan 2020. We poured out our creative hearts by drawing robots, KLCC and of course flying cars all over the sky. Back then, we believed that in 20 years or more to come, the world would evolve like what we had creatively imagined.

Fast forward to 2019, nothing much has changed and in 2020-2021, it’s still a dream for us and even far apart from our imagination due to the global pandemic outbreak. It affected the world including Malaysia and changed the lifestyles of many such as no more outings without a mask, travel restrictions and working from home (WFH) has become a norm. One of the struggles that many people face when it comes to WFH is to juggle between work and house chores:

Tired of cooking

Preparing and cooking 3 meals per day especially for the entire family can become a chore after a while, especially the cleaning afterwards. Your kitchen is a mess now with tons of plate, oily floor and the most headache part is the food smell being trapped inside your house and sometimes it continues to linger even after you wake up the next morning. (sigh)

Pets fur everywhere

Pets like cats and dogs are cute but if you have a pet, you know how frustrating their drop of hair/ fur can be. You literally see the hair flying in the air or has firmly landed on the floor or attached to your furniture. And of course, you vacuum the fur everyday to ensure your family members are away from respiratory issues or allergies. It definitely drains your energy and you may feel extremely tired.

Getting rid of germs and bacteria

Due to the pandemic outbreak last year, no doubt that you are more aware and emphasise on the hygiene level at home. Especially parents are more alert to frequently sanitise things at home eg. door knobs, toys, remote controls etc to ensure your kids are protected from harmful germs and bacteria.

But sometimes it’s still unavoidable even after many rounds of cleaning and sanitising, tiny air pollutants which we could not see from our naked eyes may still enter from different entry points.

It is definitely not easy to juggle both your work and house chores daily. But, there is a way to reduce your burden. Initial InspireAir 72- air purifier that purifies and sanitises air up to 72m2  indoor space by eliminating 95% of air pollutants. It can be placed in your respective rooms to improve the indoor air quality for you and your family. It contains multilayer filters that remove harmful airborne particles down to 0.3 microns which include bacteria and pollen. Once the air purifier is set to run, it will start to clean and sanitise the air immediately and give a constant reading of the indoor air quality within the coverage vicinity.

Now, with good indoor air quality at home, it helps to protect you and your loved ones from harmful germs and bacteria while increasing productivity and performance at work and at the same time enjoy your leisure activities at peace. Be sure not to miss out the attractive deal for InspireAir 72. Head on to Initial Hygiene Malaysia now to find out more.

About Rentokil Initial Malaysia

Rentokil Initial is part of an international network of over 70 countries with 35,500 colleagues, more than 100 years of combined experience, and a great track record of providing reliable and trustworthy services to businesses globally.

Established in Malaysia for over 50 years, we are the experts delivering essential services in areas such as hygiene and pest control the foundation of businesses – so our customers can focus on what they do best. Rentokil Initial is characterised by efficient management that supports a national network across Malaysia. That means there’s always a Rentokil Initial service technician nearby when a customer needs one – and that we have the range and depth of resources to provide consistent quality service to customers. This makes Rentokil Initial a trusted brand of many different customers ranging from residential, SMEs to large organisations.

For more information on our services, please contact:

Initial hygiene : 1800 880 388
initial.com.my

Rentokil pest control : 1300 886 911
rentokil.com.my 

SOURCE : Rentokil Initial Malaysia

· Expanding existing COVID-19 vaccine research collaboration which began in July 2020.
· Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19 vaccines)
· Exclusive license for Republic of Korea and multiple Southeast Asian countries, if successful
· Manufacturing protocols to produce vaccines from C1 have been successfully transferred and reproduced at Medytox

JUPITER, Fla., March 23 (Bernama-GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics at flexible commercial scales, today announced that the Company is expanding its partnership with South Korea’s Medytox, Inc. (“Medytox”), a global biopharmaceutical company with sales in approximately 60 countries. Dyadic and Medytox will co-develop C1 manufactured COVID-19 vaccines and/or boosters, which will, if successful, be used to immunize people against two or more of the current and future COVID-19 variants. This project can provide dedicated local supply, to help combat COVID-19, in this region of the world.

Dr. Gi-Hyeok Yang, Sr, Executive Vice President and Head of Research and Development at Medytox stated, “We are very excited to extend our collaboration with Dyadic and their C1 technology platform to partner in the co-development of C1 manufactured COVID-19 vaccines.” Dr. Yang continued, “We have been working closely with Dyadic since July 2020, when we obtained access to their C1 expression platform and experienced the remarkable versatility and high productivity of the C1 platform. Based on our experience and comparing the C1 technology platform against several other expression platforms such as CHO and insect cells, we believe that the fungi-derived C1 expression system is the most realistic technology to develop and manufacture multi-valent (i.e., tri-valent, and tetra-valent) vaccines, rapidly and affordably, against COVID-19 mutant viruses without the need for a large-scale bioreactor facility. Medytox has confidence that the C1 technology platform can play a critical role in helping combat COVID-19, which may continue to persist as a seasonal influenza and necessitate COVID-19 variant vaccine shots every year. We look forward to gaining additional experience with the C1 technology as it has potential for use in developing and producing a growing number of vaccines, drugs, and other biological products in addition to COVID-19. As a biopharmaceutical company, with multiple successful commercial products, we look forward to leveraging our proven world-class research and development and commercialization capabilities to expeditiously bring potential new C1 manufactured COVID-19 variant vaccines to market, to combat this deadly infectious disease.”

Mark Emalfarb, Dyadic’s Founder and Chief Executive Officer commented, “If global efforts to eradicate the current pandemic are to be successful, there needs to be more efficient, affordable, and flexible ways to develop and manufacture vaccines globally, that can stop the spread of COVID-19. At Dyadic, we listened to early warnings from the scientific community and, as early as 2015, we joined with European human and animal health experts in the Zoonosis Anticipation Preparedness Initiative (ZAPI).In 2018, we expanded this effort to further develop our C1 gene expression platform for use in facilitating a fast, coordinated, and practical response to emerging infectious diseases.”Mr. Emalfarb continued, “If we are to achieve a better future, we must reduce or eliminate the risk of future pandemics, by acting now to invest in crucial research and development to optimize vaccination and drug strategies and technologies. A growing number of global scientists, industry and government agencies believe the C1 platform is positioning Dyadic as the partner of choice for high volume, low-cost, next generation vaccine and drug manufacturing, including COVID-19, influenza and other vaccines.”

About Medytox, Inc.
Medytox is a research-based bio pharmaceutical company which developed a botulinum toxin product for the first time in Korea (the fourth in the world), and engages in the development, manufacture, marketing, and sales of neurotoxin products as its main business. Since its establishment in 2000, Medytox has developed and evolved into a global world-class R&D company with the successful launch of its main neurotoxin product. Today, Medytox’s neurotoxin products are sold in about 60 countries with millions of people having already received therapeutic or aesthetic treatments. For more information regarding Medytox, go to: www.medytox.com.

About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large-scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. As the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs, and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic’s website at http://www.dyadic.com for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at http://www.dyadic.com.

Contact:

Dyadic International, Inc.
Mark Emalfarb
Chief Executive Officer
Phone: (561) 743-8333
Email: memalfarb@dyadic.com

SOURCE: Dyadic International, Inc.

–BERNAMA

KUALA LUMPUR, March 23 (Bernama) — PRA Health Sciences has announced the launch of its Patient-Centric Trial Development Toolkit, available now to clinical development sponsors focusing on rare diseases.

Developed by PRA’s Center for Rare Diseases in collaboration with PRA’s Rare Disease Advisory Committee (RDAC) and other patient stakeholders, the toolkit includes four digital resources designed to mitigate risks that frequently occur in rare disease clinical trials.

According to a statement, the toolkit also introduces and affirms new patient-centric practices that promote trial participation.

“The main purpose of the toolkit is to guide sponsors in taking a more patient-centric approach in developing clinical trials,” said PRA Health Sciences Senior Vice-President, Center for Rare Diseases, Scott Schliebner, MPH.

“As an example, the toolkit includes a risk assessment tool that clinical development teams can use to identify risk to the efficiency of a clinical programme. The risks that are identified are usually real world burdens for participants, and the tool provides risk mitigation strategies and solutions for sponsors to consider.”

PRA’s rare disease experts and RDAC members recognised a gap in the availability of structured tools for operationalising patient-centricity in rare disease clinical development.

While the Patient-Centric Trial Development Toolkit does focus on lessening the burden on patients to participate in clinical research, there are also several key benefits for sponsors, including avoiding significant costs related to inefficiency, high trial dropout rates and protocol amendments.

The Patient-Centric Trial Development Toolkit is available at no cost and can be downloaded at https://prahs.com/insights/patient-centric-trial-development-toolkit.

— BERNAMA

SELANGOR, March 22 (Bernama) — In the spirit of ”Malaysia, We Are In This Together!” GCH Retail Malaysia continues in giving back to the community and doing its part for all Malaysians in these unprecedented times. As a show of gratitude and unity in fighting the Covid-19 pandemic, GCH Retail Malaysia has contributed RM25,000 worth of goods, consisting of more than 2,000 mineral bottles, 600 of hand sanitizers, as well as thousands of popular Meadows products to medical frontliners and patients at the Quarantine Centre including MAEPS Serdang, Quarantine Centre on 24 February 2021 and other hospital on 5 March 2021.

GCH Retail Malaysia deeply understand on the effort of medical teams and hospital support staff who are working around the clock and putting their lives at risk in the fight against COVID-19, with the intention to provide optimum care to their patients. 

About GCH Retail (Malaysia) Sdn Bhd

GCH Retail (Malaysia) Sdn. Bhd., (GCH Retail) a subsidiary of Dairy Farm International, is the operator of Giant hypermarkets and supermarkets chain; TMC, Cold Storage, Mercato, GEkspres, and ShopSmart. Keeping abreast of the latest market trends, GCH Retail continues to deliver modern retail experiences and avails Malaysian customers to a wide array of products and produce, including quality value selections as well as premium and exclusive offerings.

Please click here for photos 

Photo 1: Frontliner representatives, lead by Dr. Shahabuddin Ibrahim, the Director of MAEPS Serdang Quarantine and Treatment Centre for COVID 19, showing their thumbs up during the handover session.

Photo 2: David Chiam, GCH Retail Malaysia representative handing over the contribution to Dr. Shahabuddin Ibrahim, the Director of MAEPS Serdang Quarantine and Treatment Centre for COVID-19.

Photo 3: David Chiam, GCH Retail Malaysia representative handing over the contribution to Kol. Dr. Arieza Mohd Yusak, the Deputy Director of MAEPS Serdang Quarantine and Treatment Centre for COVID-19.

SOURCE: GCH Retail (Malaysia) Sdn Bhd

FOR MORE INFORMATION, PLEASE CONTACT:
Name: KHAIRUNNISYA HANIS 
Corporate Communications Executive 
Corporate Affairs
Tel: +603 5544 8888 ext 8863 / +6018-7609 046  
Fax: +603-5512 4767  
Email: khairunnisya@giant.com.my 
Website: http://www.giant.com.my

–BERNAMA